CRDFNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Cardiff Oncology, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$0.89−0.02 (-1.71%)
Close on Oct 19, 2026
- Market cap
- $60.58M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$1.3043 (−59.56%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Cardiff Oncology, Inc. saw revenue fall 7.0% to $508.00K over the twelve months to Jun 30, 2026. Free cash flow was -$37.97M.
Revenue
$508.00K
-7.0% vs. a year earlier
Operating income
-$42.27M
TTM Q2 2026
Free cash flow
-$37.97M
FY2025
EPS, diluted
-$0.60
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $60.58M
- P/E ratio
- –
- Price to sales
- 119.25
- Price to book
- 2.28
- Dividend yield
- –
- Free cash flow yield
- -62.67%
Fundamentals
- Revenue
- $508.00K
- Net income
- -$40.05M
- EPS, diluted
- -$0.60
- Free cash flow
- -$37.97M
- Book value per share
- $0.39
- Diluted shares
- 68M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$508.00K-7.0% YoY
Gross profit
–
Operating income
-$42.27M
Net income
-$40.05M
EPS, diluted
-$0.60
Free cash flow
–
Reported periodTrailing twelve months